Monte Rosa Therapeutics is developing molecular glue degrader medicines that could be used to treat both cancer and immunological disorders. Novartis has shown interest in a Monte Rosa drug candidate, MRT-6160, designed to target a protein associated with autoimmune disease and has paid $150 million for global rights to the program. The drug is currently in Phase 1 testing and has shown promising preclinical data in inflammatory bowel disease and rheumatoid arthritis. Monte Rosa’s agreement with Novartis includes potential milestone payments of up to $2.1 billion. This partnership allows Novartis to expand its protein degradation scope to autoimmune disease.
Source link
Health Information Management